Du är här

2016-02-18

Active Biotech: Active Biotech AB Year-end report January - December 2015

Laquinimod
· In April, it was announced that the first patient was enrolled to ARPEGGIO,
which is evaluating laquinimod's potential for treatment of primary
progressive multiple sclerosis (PPMS)
· In June, it was announced that the company was to focus its operations on
the laquinimod projects and adjust the organization accordingly
· In June, it was announced that the Phase 3 laquinimod study CONCERTO was
fully enrolled
· In October, Teva presented data concerning laquinimod for the treatment of
multiple sclerosis at the ECTRIMS congress
· The high dose group in the clinical studies CONCERTO, ARPEGGIO and LEGATO
has been discontinued due to cardiovascular events
· The study results from both the pivotal clinical Phase 3 study CONCERTO in
relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO,
evaluating laquinimod for the treatment of primary progressive multiple
sclerosis (PPMS), are expected in the first half of 2017

Tasquinimod

· In April, it was announced that Active Biotech and Ipsen were to discontinue
development of tasquinimod for the treatment of prostate cancer
· The final results from the 10TASQ10 study were presented in September 2015
at the ECC conference and demonstrated that while the primary endpoint was
reached and tasquinimod treatment resulted in a prolonged radiographic
progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on
rPFS did not translate into an improved OS

ANYARA, Paquinimod (57-57) and ISI
· Out-licensing activities are continuing

Financial summary

---------------------------------------------------------------------------------
| MSEK Oct - Dec Jan. - Dec. |
| 2015 2014 2015 2014 |
| |
| Net sales 5.0 2.9 16.3 10.4 |
| |
| Operating loss -28.2 -55.6 -177.9 -228.5 |
| |
| Loss for the period -40.8 -57.0 -193.5 -231.5 |
| |
| Loss per share, before and after dilution (SEK) -0.45 -0.73 -2.15 -3.02 |
| |
| Cash and cash equivalents 103.6 328.5 |
---------------------------------------------------------------------------------
For further information, please contact
:

Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

The report is also available atwww.activebiotech.com.

Active Biotech AB Year-end report January - December 2015
http://hugin.info/1002/R/1986986/729147.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

HUG#1986986

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.